688575.SH
亚辉龙
SSE · Healthcare · Medical - Specialties · CN
CNY 9.20
−3.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.8B | 2.0B | 2.1B | 4.0B |
| Cost of Revenue | 617.3M | 636.6M | 698.5M | 886.8M | 1.8B |
| Gross Profit | 1.2B | 1.2B | 1.3B | 1.2B | 2.1B |
| Operating Expenses | |||||
| R&D Expense | 304.4M | 304.9M | 336.7M | 317.2M | 240.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 201.2M | 194.4M | 172.2M | 172.3M | 130.9M |
| Selling & Marketing Expense | 454.9M | 448.8M | 434.7M | 395.4M | 493.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.0B | 987.0M | 970.4M | 888.4M | 886.8M |
| Cost and Expenses | 1.6B | 1.6B | 1.7B | 1.8B | 2.7B |
| Operating Income (EBIT) | 134.2M | 111.5M | 315.1M | 340.5M | 1.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 103.6M | 94.5M | 311.7M | 334.1M | 1.2B |
| Income Tax Expense | 28.2M | 26.1M | 39.5M | 54.9M | 165.2M |
| Bottom Line | |||||
| Net Income | 31.1M | 23.3M | 301.5M | 355.0M | 1.0B |
| Earnings from Cont. Ops | 75.4M | 68.3M | 272.2M | 279.2M | 1.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 31.1M | 23.3M | 301.5M | 355.0M | 1.0B |
| Per Share | |||||
| Basic EPS | CN¥0.06 | CN¥0.04 | CN¥0.53 | CN¥0.63 | CN¥1.79 |
| Diluted EPS | CN¥0.06 | CN¥0.04 | CN¥0.53 | CN¥0.62 | CN¥1.78 |
| Revenue Per Share | CN¥2.99 | CN¥3.10 | CN¥3.54 | CN¥3.64 | CN¥7.04 |
| Shares | |||||
| Basic Shares Outstanding | 598.4M | 583.5M | 568.9M | 563.5M | 565.4M |
| Diluted Shares Outstanding | 598.4M | 583.5M | 568.9M | 563.5M | 565.4M |
| Profitability Metrics | |||||
| EBITDA | — | 407.8M | 565.8M | 543.4M | 1.4B |
| D&A | — | 296.4M | 250.7M | 202.8M | 152.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026